Home>>Signaling Pathways>> Neuroscience>> Ophthalmology>>5-trans Latanoprost

5-trans Latanoprost (Synonyms: 5,6trans Latanoprost)

Catalog No.GC41094

Latanoprost is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug.

Products are for research use only. Not for human use. We do not sell to patients.

5-trans Latanoprost Chemical Structure

Cas No.: 913258-34-1

Size Price Stock Qty
1mg
$101.00
In stock
5mg
$455.00
In stock
10mg
$809.00
In stock
50mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Latanoprost is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug. 5-trans Latanoprost is an isomer of latanoprost wherein the double bond between carbons 5 and 6 has been changed from cis (Z) to trans (E). The trans isomer of latanoprost occurs as an impurity of between 2-5% in most commercial preparations of the bulk drug product. The present compound was prepared primarily as an analytical standard for detection and quantitation of this impurity. From what can be inferred from the study of other trans isomers of F-type prostaglandins, 5-trans latanoprost's biological activity is likely to be similar to that of the cis isomer. However, there are no specific published reports on the biological activity, and on the intraocular hypotensive activity in particular, of 5-trans latanoprost.

Reviews

Review for 5-trans Latanoprost

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 5-trans Latanoprost

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.